Company news

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) news

Every Shuttle Pharmaceuticals Holdings, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) news

Press releases & updates

Shuttle Pharmaceuticals Holdings, Inc. Announces Receipt of NASDAQ Noncompliance Letter

Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 11, 2026, at 12:01 a.m., Eastern Time

Shuttle Pharmaceuticals and United Dogecoin Announce Purchase Order for up to 3,000 ElphaPex Dogecoin and Litecoin Mining Rigs

RETRANSMISSION: Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows

Shuttle Pharmaceuticals Launches Autonomous Self Reasoning AI Agent for Scientific Workflows

E.F. Hutton & Co. Serves as Exclusive Placement Agent on Shuttle Pharmaceuticals’ $3.5 Million Public Offering

Shuttle Pharmaceuticals Announces $3.5 Million Public Offering

Shuttle Pharmaceuticals Acquires AI Health Platform

Shuttle Pharmaceuticals Announces Above-the-Market $2.5 Million Private Placement at Effective Price per Share of $4.00

Shuttle Pharma Positions to Become the First Self-Learning Biotech After Definitive LOI to Acquire Molecule.AI (NASDAQ:SHPH)

Shuttle Pharmaceuticals to Acquire AI Molecular Modeling and Predictive Analytics Platform

Shuttle Pharma Turns Radiation Into a Smart Weapon With Definitive LOI for Molecule.ai (NASDAQ:SHPH)

Shuttle Executes LOI with Molecule.ai

Shuttle to Enter $3.24 Billion AI Pharmaceutical Market

Shuttle Pharma Provides Second Quarter 2025 Corporate Update

Shuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market

Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market

Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time

Shuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance Initiative

Shuttle Pharma Appoints George Scorsis Chairman of the Board of Directors

Shuttle Pharma Provides Corporate Update

Shuttle Pharma FDA Orphan-Drug Nears Patient Enrollment Milestone for Phase 2 Clinical Trial

Shuttle Pharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to...

Shuttle Pharma Announces Closing of $5.75 Million Underwritten Offering

Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering

Shuttle Pharma Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities

Shuttle Pharma Provides Corporate Update and Reports 2024 Results

Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Gliobl...

Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program

Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA...

Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharma Pays Off Senior Secured Convertible Note

Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease

Shuttle Pharma Provides Second Quarter 2024 Corporate Update

Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)

Shuttle Pharma Ready to Enroll Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma

Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer

Shuttle Pharma Provides First Quarter 2024 Corporate Update

Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update

Shuttle Pharma Announces Its Intent to Pursue a Rights Offering

Shuttle Pharmaceuticals Receives FDA Approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Gl...

Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma

Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update

Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement